CSL wins $230 million H1N1 vaccine order
Monday, 01 June, 2009
CSL's US subsidiary, CSL Biotherapies, has signed a $230 million (USD180 million) contract with the US Department of Health and Human Services (HHS) to provide Novel A (H1N1) influenza vaccine in bulk form.
CSL has also announced it will supply the Novel A (H1N1) vaccine to Australia.
The vaccine will be manufacturered at CSL's facility in Parkville, Victoria, and will support the HHS pre-pandemic influenza preparation efforts.
The new vccine will be tested in clinical trials funded by HHS.
CSL has declared that it will maintain its committment to supply seasonal influenza vaccines to Australia, the US and other markets.
TGA approves first treatment for geographic atrophy
Australia has become the first country outside of the United States to approve the use of the...
Damaged RNA, not DNA, revealed as main cause of acute sunburn
Sunburn has traditionally been attributed to UV-induced DNA damage, but it turns out that this is...
Multi-ethnic studies identify new genes for depression
Two international studies have revealed hundreds of previously unknown genetic links to...
